moxisylyte has been researched along with Impotence in 19 studies
Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)
Excerpt | Relevance | Reference |
---|---|---|
"We compared the efficacy and safety of alprostadil alpha-cyclodextrin and moxisylyte chlorhydrate to induce erections adequate for sexual intercourse in a prospective, randomized, parallel double-blind study in patients with erectile dysfunction." | 9.08 | Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. ( Albrecht, D; Buvat, J; Costa, P; Lecocq, B; Morlier, D; Stegmann, B, 1998) |
"Moxisylyte is a competitive noradrenaline antagonist, acting preferentially on post-synaptic alpha-1 adrenoceptors." | 6.40 | Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence. ( Bressolle, F; Marquer, C, 1998) |
"Moxisylyte chlorhydrate is a selective alpha-blocker of the post-synaptic alpha 1-adrenoreceptors." | 5.29 | [Prolonged use of moxisylyte chlorhydrate (Icavex) by intracavernous self-injections in the treatment of impotence. Evaluation of long-term tolerance]. ( Arvis, G; Rivet, G; Schwent, B, 1996) |
"We compared the efficacy and safety of alprostadil alpha-cyclodextrin and moxisylyte chlorhydrate to induce erections adequate for sexual intercourse in a prospective, randomized, parallel double-blind study in patients with erectile dysfunction." | 5.08 | Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction. ( Albrecht, D; Buvat, J; Costa, P; Lecocq, B; Morlier, D; Stegmann, B, 1998) |
"We assessed the efficiency and tolerance of the alpha-blocking agent moxisylyte in 2 double-blind studies versus placebo performed in 12 neurogenic patients with spinal cord lesions and in 61 patients presenting with either psychogenic impotence (30) or erectile dysfunction that was predominantly neither psychogenic, hormonal nor neurogenic (31)." | 5.07 | Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo. ( Bondil, P; Bressolle, F; Colson, MH; Costa, P; Sarrazin, B; Saudubray, F, 1993) |
"We tested the possibility of using intracavernous injections of the alpha-blocking agent moxisylyte (6-acetoxy-thymoxy-ethyl-dimethylamine) as treatment of erectile impotence." | 5.06 | Safety of intracavernous injections using an alpha-blocking agent. ( Buvat, J; Buvat-Herbaut, M; Lemaire, A; Marcolin, G, 1989) |
" The literature search was restricted to articles published in English, French, and Spanish up to November 2014 using the key words alprostadil, papaverine, moxisylite, alpha-blocking agent, phentolamine, intracavernous injection, spinal cord injuries, paraplegia, quadriplegia, and erectile dysfunction." | 4.93 | Intracavernous Injections in Spinal Cord Injured Men With Erectile Dysfunction, a Systematic Review and Meta-Analysis. ( Bonan, I; Chéhensse, C; Chochina, L; Damphousse, M; Giuliano, F; Manunta, A; Naudet, F, 2016) |
"Alprostadil was used 51 times, moxisylite nine times and papaverine four times." | 2.70 | [Intracavernous injections in the treatment of erectile dysfunction in spinal cord injured patients: experience with 36 patients]. ( Boiteau, F; Boyer, F; Dizien, O; Laffont, I; Lebib Ben Achour, S, 2001) |
"Moxisylyte is a competitive noradrenaline antagonist, acting preferentially on post-synaptic alpha-1 adrenoceptors." | 2.40 | Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence. ( Bressolle, F; Marquer, C, 1998) |
"Moxisylyte chlorhydrate is a selective alpha-blocker of the post-synaptic alpha 1-adrenoreceptors." | 1.29 | [Prolonged use of moxisylyte chlorhydrate (Icavex) by intracavernous self-injections in the treatment of impotence. Evaluation of long-term tolerance]. ( Arvis, G; Rivet, G; Schwent, B, 1996) |
"Moxisylyte hydrochloride is an agent with potential clinical and research uses capable of producing erection when injected intra-cavernously." | 1.28 | Effect of moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue. ( Imagawa, A; Kawanishi, Y; Kimura, K; Tamura, M, 1989) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (21.05) | 18.7374 |
1990's | 13 (68.42) | 18.2507 |
2000's | 1 (5.26) | 29.6817 |
2010's | 1 (5.26) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chochina, L | 1 |
Naudet, F | 1 |
Chéhensse, C | 1 |
Manunta, A | 1 |
Damphousse, M | 1 |
Bonan, I | 1 |
Giuliano, F | 1 |
Porst, H | 1 |
Buvat, J | 4 |
Buvat-Herbaut, M | 2 |
Lemaire, A | 3 |
Marcolin, G | 2 |
Costa, P | 5 |
Sarrazin, B | 2 |
Bressolle, F | 3 |
Mottet, N | 1 |
Louis, JF | 2 |
Saudubray, F | 2 |
Navratil, H | 2 |
Colson, MH | 1 |
Bondil, P | 2 |
Andro, MC | 2 |
Saur, P | 1 |
Hermabessiere, J | 1 |
Herbaut-Buvat, M | 1 |
Arvis, G | 1 |
Rivet, G | 1 |
Schwent, B | 1 |
Morlier, D | 1 |
Lecocq, B | 1 |
Stegmann, B | 1 |
Albrecht, D | 1 |
Gingell, JC | 1 |
Marquer, C | 1 |
de Tejada, IS | 1 |
Garvey, DS | 1 |
Schroeder, JD | 1 |
Shelekhin, T | 1 |
Letts, LG | 1 |
Fernández, A | 1 |
Cuevas, B | 1 |
Gabancho, S | 1 |
Martínez, V | 1 |
Angulo, J | 1 |
Trocha, M | 1 |
Marek, P | 1 |
Cuevas, P | 1 |
Tam, SW | 1 |
Lebib Ben Achour, S | 1 |
Laffont, I | 1 |
Boyer, F | 1 |
Boiteau, F | 1 |
Dizien, O | 1 |
Imagawa, A | 1 |
Kimura, K | 1 |
Kawanishi, Y | 1 |
Tamura, M | 1 |
Schouman, M | 1 |
Amer, M | 1 |
Jardin, A | 1 |
Bensadoun, H | 1 |
Benoit, G | 1 |
Puech, A | 1 |
Alexandre, L | 1 |
3 reviews available for moxisylyte and Impotence
Article | Year |
---|---|
Intracavernous Injections in Spinal Cord Injured Men With Erectile Dysfunction, a Systematic Review and Meta-Analysis.
Topics: Alprostadil; Erectile Dysfunction; Humans; Male; Moxisylyte; Papaverine; Penile Erection; Prospectiv | 2016 |
New developments in self-injection therapy for erectile dysfunction.
Topics: Alprostadil; Calcitonin Gene-Related Peptide; Chlorpromazine; Dose-Response Relationship, Drug; Erec | 1998 |
Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence.
Topics: Absorption; Animals; Drug Administration Routes; Erectile Dysfunction; Humans; Male; Moxisylyte; Ran | 1998 |
7 trials available for moxisylyte and Impotence
Article | Year |
---|---|
[Treatment of impotence with intracavernous auto-injections: moxisylyte diminishes the risks compared to papaverine].
Topics: Adult; Aged; Erectile Dysfunction; Humans; Injections; Male; Middle Aged; Moxisylyte; Papaverine; Pe | 1993 |
Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Erectile Dysfunction; Humans; Male; Mi | 1993 |
[Effectiveness of and tolerance to intracavernous injection of moxisylyte in patients with erectile dysfunction: effect/dose relationship versus placebo].
Topics: Adult; Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Erectile Dys | 1995 |
[Efficacy and tolerance of intracavernous injection of moxisylyte in patients with erectile dysfunction: double-blind placebo-controlled study].
Topics: Adult; Aged; Double-Blind Method; Erectile Dysfunction; Humans; Injections; Male; Middle Aged; Moxis | 1995 |
Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; alpha-Cyclodextrins; Alprostadil; Chronic Disease; Cyclod | 1998 |
[Intracavernous injections in the treatment of erectile dysfunction in spinal cord injured patients: experience with 36 patients].
Topics: Adult; Alprostadil; Erectile Dysfunction; Humans; Male; Moxisylyte; Papaverine; Patient Satisfaction | 2001 |
Safety of intracavernous injections using an alpha-blocking agent.
Topics: Adult; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged; Moxisylyte; Papaverine; | 1989 |
9 other studies available for moxisylyte and Impotence
Article | Year |
---|---|
The rationale for prostaglandin E1 (alpha-alprostadil) in the management of male impotence.
Topics: Alprostadil; Erectile Dysfunction; Humans; Impotence, Vasculogenic; Male; Molsidomine; Moxisylyte; P | 1995 |
Is the volume injected a parameter likely to influence the erectile response observed after intracavernous administration of an alpha-blocking agent?
Topics: Adult; Erectile Dysfunction; Humans; Injections; Male; Moxisylyte; Penile Erection; Solutions; Solve | 1993 |
[Treatment of erectile insufficiency].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Alprostadil; Erectile Dysfunction; Humans | 1995 |
Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1.
Topics: Adult; Aged; Alprostadil; Dose-Response Relationship, Drug; Erectile Dysfunction; Fibrosis; Humans; | 1996 |
[Prolonged use of moxisylyte chlorhydrate (Icavex) by intracavernous self-injections in the treatment of impotence. Evaluation of long-term tolerance].
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Erectile Dysfunction; Follow-Up Studies; Humans; Male; Mi | 1996 |
Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists as potential agents for the treatment of impotence.
Topics: Adrenergic alpha-Antagonists; Animals; Cyclic GMP; Drug Design; Endothelins; Erectile Dysfunction; H | 1999 |
Effect of moxisylyte hydrochloride on isolated human penile corpus cavernosum tissue.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; In Vitro Te | 1989 |
[Value of the visual stimulation test (VST) as initial paraclinical test in the study of erectile impotence. Classification of psychogenic impotence using computerized rigidimetry. The value of thymoxamine].
Topics: Adult; Aged; Erectile Dysfunction; Humans; Male; Middle Aged; Moxisylyte; Papaverine; Penile Erectio | 1989 |
[What can be expected of intracavernous injections?].
Topics: Adult; Aged; Apomorphine; Erectile Dysfunction; Humans; Injections; Injections, Subcutaneous; Male; | 1988 |